Market Insights-arkiv - Page 2 of 6 - Biosector Ltd.

by Stefan Sandström

Infographic: Why CNS is the next Battleground for Organoids

0

Business executive overlooking Japan’s pharmaceutical opportunity, with Mount Fuji, Tokyo skyline, Shinkansen, laboratory scientists, DNA helix, medicine vials, and an upward growth graph.

by Stefan Sandström

Catching Pharmaceutical Opportunities in Japan’s Reinvented Pharmaceutical Arena

For too long, if you ask me, the Japan pharmaceutical market opportunity has been treated as […]

0

Illustration of a company at a crossroads choosing among three market access routes into Japan: Own MAH, 3rd party DMAH, or Japanese partner as MAH, shown as three numbered roads leading toward a Tokyo cityscape.

by Stefan Sandström

MAH, DMAH, or a Japanese Partner: A Strategic Choice You Need to Make Before Entering Japan

Entering Japan is not only about regulatory approval, launch planning, and commercial ambition. One of the […]

0

Illustration of the supply chain for targeted alpha therapy in Japan using Astatine-211. The graphic shows domestic cyclotron production, GMP radiochemistry and automated purification, a national site network strategy, time-critical logistics across Japan due to the 7.2-hour half-life, and outpatient administration of the radiopharmaceutical.

by Stefan Sandström

Targeted Alpha Therapy in Japan: why Domestic ²¹¹At Supply Matters for Scale

Radioligand therapy is now a board-level topic in Japan, not because the science is new, but […]

0

Abstract wide illustration showing Japan drug pricing from listing to post-launch revisions, using blue shapes on a sand background with red trigger markers.

by Stefan Sandström

December 15, 2025

Japan FY2026 Drug Pricing Reform Draft: What Changes at Listing, What Tightens After Launch

On December 12, 2025, Japan’s Ministry of Health, Labour and Welfare (MHLW) tabled a draft outline […]

0

Photorealistic scene of a consultant in a Tokyo meeting room connecting a foreign company with Japanese pharma executives.

by Stefan Sandström

December 11, 2025

Why Japanese Targets Like You, Listen to You – and Still You Don’t Succeed

You fly in, you present, you charm the room. Heads nod. The technical team likes your […]

0

Abstract flat illustration of Japanese blockbuster drugs falling off a 2026 PMP price cliff with coloured bars and icons for key therapy areas.

by Stefan Sandström

December 8, 2025

Japan’s FY2026 Drug Price Revision: PMP Return and the End of the Long-Tail Blockbuster

Japan’s pharmaceutical market is about to run a high-stakes experiment in how hard a mature health […]

0

Abstract illustration of Toronto’s biomedical innovation cluster centered on MaRS, research institutes, and startups.

by Stefan Sandström

December 2, 2025

MaRS and Beyond: How Toronto Engineered a Biomedical Growth Engine

Something quietly extraordinary has been happening in the heart of downtown Toronto. Within one of the […]

0

Selfie on the BioJapan 2025 exhibition floor: attendee in foreground, crowded aisles with posters and company booths, “AIST” jacket visible, signage directing to partnering zones.

by Stefan Sandström

October 17, 2025

Japan’s Entrepreneurial Life Science Boom: How Policy, Capital, and Clusters Are Rewriting the Playbook

The surge I sensed at BioJapan 2025 in October reflects deliberate engineering rather than hype: targeted […]

0

Abstract landscape of sand-toned islands linked by light-blue channels, with dark-blue bio-factory shapes and red markers suggesting biologics flow across Japanese hubs.

by Stefan Sandström

October 14, 2025

Japan’s Biotech Surge: How You Can Convert the Startup Boom into Revenue

A New Order is taking shape in Japan’s life sciences. Conference floors are packed, university benches […]

0